Anabolic therapies

Nancy E Lane; Stuart L. Silverman

doi:10.1007/s11914-010-0005-4

Anabolic therapies

Nancy E Lane, Stuart L. Silverman

General Medicine, Geriatrics, and Bioethics

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1-34) is the first US Food and Drug Administration-approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone-related protein PTHrP, a calciumregulating hormone similar to PTH.

Original language	English (US)
Pages (from-to)	23-27
Number of pages	5
Journal	Current Osteoporosis Reports
Volume	8
Issue number	1
DOIs	https://doi.org/10.1007/s11914-010-0005-4
State	Published - Mar 2010

Keywords

BMD
BMP
Osteoporosis
PTH
Sclerostin
Wnt

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism

Access to Document

10.1007/s11914-010-0005-4

Cite this

@article{d1e0662e33ca493ab2a0a0111465f63f,

title = "Anabolic therapies",

abstract = "The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1-34) is the first US Food and Drug Administration-approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone-related protein PTHrP, a calciumregulating hormone similar to PTH.",

keywords = "BMD, BMP, Osteoporosis, PTH, Sclerostin, Wnt",

author = "Lane, {Nancy E} and Silverman, {Stuart L.}",

year = "2010",

month = mar,

doi = "10.1007/s11914-010-0005-4",

language = "English (US)",

volume = "8",

pages = "23--27",

journal = "Foodborne Pathogens and Disease",

issn = "1744-165X",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Anabolic therapies

AU - Lane, Nancy E

AU - Silverman, Stuart L.

PY - 2010/3

Y1 - 2010/3

N2 - The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1-34) is the first US Food and Drug Administration-approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone-related protein PTHrP, a calciumregulating hormone similar to PTH.

AB - The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1-34) is the first US Food and Drug Administration-approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone-related protein PTHrP, a calciumregulating hormone similar to PTH.

KW - BMD

KW - BMP

KW - Osteoporosis

KW - PTH

KW - Sclerostin

KW - Wnt

UR - http://www.scopus.com/inward/record.url?scp=77953621455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953621455&partnerID=8YFLogxK

U2 - 10.1007/s11914-010-0005-4

DO - 10.1007/s11914-010-0005-4

M3 - Article

C2 - 20425087

AN - SCOPUS:77953621455

VL - 8

SP - 23

EP - 27

JO - Foodborne Pathogens and Disease

JF - Foodborne Pathogens and Disease

SN - 1744-165X

IS - 1

ER -

Anabolic therapies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this